US8086442071 - Common Stock
Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry
19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region
Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials....
Science 37 Supports Phase 3 Clinical Trial with Recruitment and Enrollment, Enhancing Access for Immunocompromised Patients Across the U.S.
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities
Nearly 20 studies have successfully leveraged Science 37's medical and operational expertise to boost patient recruitment and enrollment activities....
Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions
Science 37, a leader in enhancing patient access to clinical trials, surpasses enrollment targets and helps accelerate Phase 2 rare disease study....
Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions
Science 37’s Virtual Site Model for Clinical Research Impresses in First-of-its-Kind FDA Inspection
Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program....
Partnership with Leading Biotech Company Enrolls 28% of Study Participants with 22x Greater Enrollment Velocity Compared to Traditional Brick-and-Mortar Clinical Trial Sites
Science 37's Metasite™ and Patient Recruitment Solutions together dramatically boost patient enrollment in a Phase 3 asthma clinical trial....
New patent-protected, central recruitment leverages the Science 37 Metasite™ to accelerate enrollment and dramatically reduce site burden
/PRNewswire/ -- eMed, LLC ("eMed") today announced the successful completion of the previously announced tender offer by its wholly-owned subsidiary, Marlin...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- eMed, LLC ("eMed") today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation ("Purchaser"), has...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Ademi LLP is investigating Science 37 (Nasdaq: SNCE) for possible breaches of fiduciary duty and other violations of law in its transaction...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Science 37 stockholders to receive $5.75 per share in cash
Science 37 stockholders to receive $5.75 per share in cash...
SNCE stock results show that Science 37 Hldgs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Science 37 Hldgs (NASDAQ:SNCE) just reported results for the first quarter of 2...
SNCE stock results show that Science 37 Hldgs beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Science 37 Hldgs (NASDAQ:SNCE) just reported results for the second quarter of ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Science 37 Hldgs (NASDAQ:SNCE) just reported results for the third quarter of 2...